ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

FMTX Forma Therapeutics Holdings Inc

20.01
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Forma Therapeutics Holdings Inc NASDAQ:FMTX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 20.01 19.98 19.40 0 01:00:00

Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021

06/05/2021 12:05pm

Business Wire


Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart


From Aug 2019 to Aug 2024

Click Here for more Forma Therapeutics Charts.

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will release first quarter 2021 financial results on Friday, May 14, 2021. Forma management will host an investment community conference call at 8 a.m. Eastern Time, on May 14, 2021, to discuss these financial results and provide a business update.

Investors may participate by dialing (833) 301-1146 in the U.S. or Canada, or (914) 987-7386 internationally, and by referring to Conference ID 8597396. A live webcast of the conference call will be available in the “News & Investors” section of Forma’s website at www.formatherapeutics.com.

About Forma Therapeutics

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.

Investor Contact: Mario Corso, +1 781-366-5726 Forma Therapeutics, Inc. mcorso@formatherapeutics.com

1 Year Forma Therapeutics Chart

1 Year Forma Therapeutics Chart

1 Month Forma Therapeutics Chart

1 Month Forma Therapeutics Chart

Your Recent History

Delayed Upgrade Clock